35.29
0.05 (0.14%)
Penutupan Terdahulu | 35.24 |
Buka | 35.59 |
Jumlah Dagangan | 1,197,322 |
Purata Dagangan (3B) | 1,651,300 |
Modal Pasaran | 5,616,721,408 |
Harga / Pendapatan (P/E Ke hadapan) | 90.91 |
Harga / Jualan (P/S) | 8.42 |
Harga / Buku (P/B) | 13.22 |
Julat 52 Minggu | |
Tarikh Pendapatan | 30 Jul 2025 - 4 Aug 2025 |
Margin Keuntungan | -63.86% |
Margin Operasi (TTM) | -111.59% |
EPS Cair (TTM) | -2.99 |
Pertumbuhan Hasil Suku Tahunan (YOY) | 10.10% |
Jumlah Hutang/Ekuiti (D/E MRQ) | 413.80% |
Nisbah Semasa (MRQ) | 9.66 |
Aliran Tunai Operasi (OCF TTM) | -501.78 M |
Aliran Tunai Bebas Leveraj (LFCF TTM) | -368.16 M |
Pulangan Atas Aset (ROA TTM) | -10.59% |
Pulangan Atas Ekuiti (ROE TTM) | -118.62% |
Arah Aliran Pasaran
Jangka Pendek | Jangka Sederhana | ||
Industri | Biotechnology (US) | Menurun | Menurun |
Biotechnology (Global) | Menurun | Menurun | |
Stok | Ionis Pharmaceuticals, Inc. | Menaik | Menurun |
AISkor Stockmoo
Konsensus Penganalisis | 4.0 |
Aktiviti Orang Dalam | NA |
Volatiliti Harga | -2.0 |
Purata Bergerak Teknikal | -1.5 |
Osilator Teknikal | 2.0 |
Purata | 0.63 |
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch. |
|
Sektor | Healthcare |
Industri | Biotechnology |
Gaya Pelaburan | Small Core |
% Dimiliki oleh Orang Dalam | 0.84% |
% Dimiliki oleh Institusi | 108.34% |
Pemilikan
Nama | Tarikh | Syer Dipegang |
---|---|---|
Tweedy, Browne Co Llc | 31 Dec 2024 | 3,248,863 |
Julat 52 Minggu | ||
Julat Harga Sasaran | ||
Tinggi | 64.00 (Guggenheim, 81.35%) | Beli |
Median | 55.00 (55.85%) | |
Rendah | 48.00 (JP Morgan, 36.02%) | Pegang |
Purata | 54.80 (55.29%) | |
Jumlah | 4 Beli, 1 Pegang | |
Harga Purata @ Panggilan | 35.47 |
Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
---|---|---|---|---|
Barclays | 01 Jul 2025 | 57.00 (61.52%) | Beli | 39.51 |
HC Wainwright & Co. | 26 Jun 2025 | 50.00 (41.68%) | Beli | 39.78 |
20 May 2025 | 50.00 (41.68%) | Beli | 34.47 | |
JP Morgan | 12 Jun 2025 | 48.00 (36.02%) | Pegang | 35.62 |
Guggenheim | 01 May 2025 | 64.00 (81.35%) | Beli | 31.71 |
Needham | 30 Apr 2025 | 55.00 (55.85%) | Beli | 30.71 |
15 Apr 2025 | 60.00 (70.02%) | Beli | 28.38 |
Tiada data dalam julat masa ini.
Tarikh | Jenis | Butiran |
---|---|---|
25 Jun 2025 | Pengumuman | Ionis announces Biogen to advance salanersen into SMA registrational studies based on positive interim Phase 1 results |
12 Jun 2025 | Pengumuman | Ionis announces Dr. Richard Geary, chief development officer, to retire; Dr. Holly Kordasiewicz to assume role in January 2026 |
11 Jun 2025 | Pengumuman | First patient dosed in pivotal Phase 3 REVEAL clinical study of ION582 in Angelman syndrome |
19 May 2025 | Pengumuman | Ionis announces positive topline results from Essence study of olezarsen in people with moderately elevated triglycerides |
06 May 2025 | Pengumuman | Ionis to host 2025 virtual Annual Meeting of Stockholders |
30 Apr 2025 | Pengumuman | Ionis reports first quarter 2025 financial results |
29 Apr 2025 | Pengumuman | New Harris Poll findings reveal HAE patients are unsatisfied with current prophylactic treatment options, with over 90% interested in trying new therapies |
16 Apr 2025 | Pengumuman | Ionis to hold first quarter 2025 financial results webcast |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
Keuntungan Nyata | - |
Keuntungan Tidak Nyata | - |
Dividen Diterima 2025 | - |
Jumlah Untung | - |
Pulangan Purata | - |
Kuantiti (Beli) | - |
Purata Harga (Beli) | - |
Kuantiti (Jual) | - |
Purata Harga (Jual) | - |